Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without ...
Aug 1, 2012
7
0
A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget.
Mar 25, 2024
0
0
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James), may offer a new treatment option ...
Nov 6, 2023
0
37
A team of researchers at the Medical University of Vienna has discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of a specific protein called P-glycoprotein (P-gp). This discovery ...
Oct 2, 2023
0
6
A new editorial paper was published in Oncoscience, titled, "UPR-induced ovarian cancer cell fusion: a mechanism favoring drug resistance?"
May 26, 2023
0
3
Post-surgical radiotherapy and temozolomide, a chemotherapeutic drug, targeting post-cell division is the current standard of care for glioblastoma (GBM)—the most prevalent and lethal primary tumor of the central nervous ...
Jan 18, 2023
0
6
Chromatin comprises a complex mixture of DNA and proteins that forms the structural basis of chromosomes in the cellular nuclei. When cells die, they release cell-free chromatin particles, or cfChPs, into the circulatory ...
Jan 16, 2023
0
2
Researchers from the Suzhou Institute of Biomedical Engineering and Technology (SIBEBT) of the Chinese Academy of Sciences (CAS) have revealed the reasons for the inevitable occurrence of multidrug resistance during tumor ...
May 18, 2022
0
3
In 1986, cellular biochemist Kazumitsu Ueda, currently at Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS), discovered that a protein called ABCB1 could transport multiple chemotherapeutics out of ...
Dec 29, 2020
0
53
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent ...
Dec 10, 2019
0
3
